Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 5, 2005 - Issue 2
Submit an article Journal homepage
1,694
Views
7
CrossRef citations to date
0
Altmetric
Editorial

Combining therapies for the treatment of migraine: is there a role?

Abouch Valenty Krymchantowski
Pages 145-147 | Published online: 10 Jan 2014

References

  • Stewart WF, Schechter A, Lipton RB. Migraine heterogeneity, disability, pain intensity and attack frequency and duration. Neurology 44(Suppl. 4), S24–S39 (1994).
  • Rasmussen BK. Epidemiology of headache. Cephalalgia 15, 45–68 (1995).
  • Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. Second Edition. Cephalalgia 24(Suppl. 1), 1–160 (1994).
  • Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American migraine study. Cephalalgia 16, 231–238 (1996).
  • Lipton RB, Stewart WF. Prevalence and impact of migraine. Neurol. Clin. 15, 1–13 (1997).
  • Tfelt-Hansen P, Welch KMA. General principles of pharmacological treatment of migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott Willians & Wilkins, PA, USA, 385–389 (2000).
  • Silberstein SD, Saper JR, Freitag FG. Migraine: diagnosis and treatment. In: Wolff’s Headache and Other Head Pain. Seventh Edition. Silberstein SD, Lipton RB, Dalessio DJ (Eds). Oxford University Press, NY, USA, 121–246 (2001).
  • Krymchantowski AV, Bigal ME, Moreira PF. New and emerging prophylactic agents for migraine. CNS Drugs 16(9), 611–634 (2002).
  • Pascual J, Leira R, Lainez JM. Combined therapy for migraine prevention? Clinical experience with a β-blocker plus sodium valproate in 52 resistant migraine patients. Cephalalgia 23, 961–962 (2003).
  • Krymchantowski AV, Hampshire F. Polytherapy in migraine prevention. Clinical experience with the combination of a β-blocker plus a tricyclic antidepressant plus a calcium channel blocker. Headache 44, 499–500 (2004).
  • Shachter SC. Epilepsy. Neurol. Clin. 19, 57–78 (2001).
  • Young WB, Siow HC, Silberstein SD. Anticonvulsants in migraine. Curr. Pain Headache Rep. 8(3), 244–250 (2004).
  • Krymchantowski AV, Tavares C. Weight variations in patients receiving topiramate migraine prophylaxis in a tertiary care setting. Med. Gen. Med. 6(3), 48 (2004).
  • Dodick DW. Acute and prophylactic management of migraine. Clin. Cornerstone 4, 36–52 (2001).
  • Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N. Engl. J. Med. 346, 257–270 (2002).
  • Lipton RB, Stewart WF, Cady R et al. 2000 Wolff Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 40, 783–791 (2000).
  • Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 42(Suppl. 1), 3–9 (2002).
  • Saxena P, Tfelt-Hansen P. Triptans, 5-HT1B/1D receptor agonists in the acute treatment of migraine. In: The Headaches. Second Edition. Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott Williams & Wilkins, PA, USA, 411–438 (2000).
  • Peroutka SJ. Beyond monotherapy: rational polytherapy in migraine. Headache 38, 18–22 (1998).
  • Bates D, Ashford E, Dawson R et al. Subcutaneous sumatriptan during the migraine aura. Neurology 44, 1587–1592 (1994).
  • Visser WH, de Vriend RH, Jaspers NHWM, Ferrari MD. Sumatriptan – nonresponders: a survey in 366 migraine patients. Headache 36, 471–475 (1996).
  • Dahlof CG. How does sumatriptan perform in clinical practice? Cephalalgia 15(Suppl. 15), 21–28 (1995).
  • Visser WH, de Vriend RH, Jaspers NHWM, Ferrari MD. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 47, 46–51 (1996).
  • Krymchantowski AV. Acute treatment of migraine. Breaking the paradigm of monotherapy. BMC Neurol. 28(4), 1–4 (2004).
  • Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 89(2–3), 107–110 (2001).
  • Lance JW. Headache. Ann. Neurol. 10, 1–10 (1981).
  • Wilkinson M. treatment of the acute migraine attack – current status. Cephalalgia 3, 61–67 (1983).
  • Callahan M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 26, 168–171 (1986).
  • Krymchantowski AV, Adriano M, Fernandes D. Tolfenamic acid decreases migraine recurrence when used with sumatriptan. Cephalalgia 19, 186–187 (1999).
  • Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq. Neuropsiquiatr. 58(2-B), 428–430 (2000).
  • Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 22, 309–312 (2002).
  • Krymchantowski AV, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol. 4(1), 10 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.